Most important, our findings are consistent with the preclinical and clinical data showing that sulfonylurea antagonists reduce plasma MMP-9 levels and hemorrhagic transformation in cerebral ischemia [19–22]. This evidence concerns the gene MMP9 and Cerebral ischemia.